Is heart failure on the rise in the US, and are we missing crucial clues about why? A recent analysis is raising eyebrows, suggesting that the drivers behind heart failure might be shifting away from traditional heart problems and towards metabolic issues. But here's where it gets controversial: some experts argue this doesn't necessarily mean we're managing the condition any better. Let's dive into the details.
Over the past 35 years, data from registries shows that the prevalence of heart failure (HF) in the United States has increased. Interestingly, when you look at specific age groups, the prevalence has remained relatively stable. This suggests that the aging of the population is a significant factor driving the overall increase in HF cases. Think of it this way: if the percentage of older people in the country increases, even if the rate of heart failure remains the same for each age group, the total number of people with heart failure will still go up.
What's even more intriguing is the changing landscape of associated risk factors. Researchers have observed a rise in obesity, diabetes, and chronic kidney disease among HF patients. Simultaneously, they've seen a decrease in reported high blood pressure, high cholesterol, and a history of prior heart attacks (myocardial infarction or MI). And this is the part most people miss: despite these shifts, cardiovascular mortality decreased in the HF population, and patients reported improvements in their overall health and physical function.
According to Dr. Ahmed Sayed and his team, "These changes reflect a complex interplay between medical innovations, better implementation, and improved clinical management of some risk factors, in parallel with increasing prevalence of other risk factors over the past four decades in the United States." In simpler terms, we're getting better at managing some traditional risk factors for heart failure, but we're simultaneously facing a surge in other, more modern risk factors. This creates a complex challenge for healthcare and health policy.
Dr. Marat Fudim, commenting on the findings, offers a compelling counterpoint. While this analysis sheds light on how HF prevalence has changed, he questions whether it truly reflects our success in managing the condition at a national level. "If I just told you we have more comorbidities and an ‘appropriate’ rise of heart failure along the way, it doesn’t sound as scary," he explains. "But then when you look at the mortality associated with those sick patients, you actually had a worsening of mortality, even though the age-adjusted heart failure prevalence is steady, including for the young individuals.” Essentially, even if the rate of heart failure isn't increasing for each age group, the severity and outcomes for those with heart failure might be worsening.
An accompanying editorial by Drs. John W. Ostrominski and Michael M. Givertz highlights potential limitations of the analysis, particularly its reliance on self-reported data. Self-reported data can be subject to recall bias and inaccuracies, as individuals may not accurately remember or report their medical history or lifestyle habits. Still, they emphasize the crucial takeaway: "These findings underscore a rapidly evolving shift from ischemic to metabolic drivers of HF." This means heart failure is increasingly being driven by metabolic issues rather than solely by blockages in the heart's blood vessels (ischemia). This transition has significant implications for how we design and conduct clinical trials for heart failure treatments, potentially requiring us to focus more on metabolic-related interventions.
Delving into the Data:
The study, utilizing data from the National Health and Nutrition Examination Survey (NHANES), included a large sample of over 83,000 participants. Among them, over 3,000 reported a history of heart failure.
The raw prevalence of HF increased from 2.1% to 3.0% between 1988 and 2023, representing a substantial relative increase. However, as mentioned earlier, this increase disappears when considering age-specific prevalence. This highlights the importance of considering the aging population when interpreting heart failure trends.
Looking at specific risk factors, the prevalence of obesity among HF patients nearly doubled, rising from 32.5% to 60.4%. Similar increases were observed for impaired glucose homeostasis, diabetes, and chronic kidney disease. Conversely, the proportions of HF patients with elevated blood pressure, high cholesterol, and a history of heart attack decreased.
The increased use of medications like ACE inhibitors/ARBs, beta-blockers, and statins likely contributed to some of these trends. Additionally, smoking rates decreased, which undoubtedly had a positive impact. The risk of cardiovascular mortality decreased in both people with and without HF, further suggesting improvements in overall cardiovascular care.
Dr. Fudim notes the limitations of the NHANES database, including missing medication data and limited lab results. He also emphasizes the importance of understanding how heart failure phenotypes (different types of heart failure) have changed over time. For instance, there's been a significant increase in heart failure with preserved ejection fraction (HFpEF), which is often linked to comorbidities like obesity and diabetes. Furthermore, because the study's data only extends to 2023, it may not fully capture the impact of the COVID-19 pandemic on heart failure.
Implications for Future Research:
The editorialists stress that these findings should shape the future of heart failure research. They advocate for trials targeting metabolic, kidney, and aging-related factors that contribute to heart failure. Trials focusing on obesity in heart failure patients are also encouraged. They also point out the need for more inclusive studies, as many previous trials have excluded patients with high BMI or advanced kidney disease. Finally, they highlight the growing importance of prevention in heart failure.
Drs. Ostrominski and Givertz conclude that the evolving needs of individuals with or at risk of HF necessitate a parallel evolution in heart failure trial concepts, design, and execution. They end with an inspiring message: “HF is not inevitable, and it is our responsibility as a cardiovascular community to demonstrate this.”
Controversy and Discussion:
This study paints a complex picture of heart failure in the US. While improvements in managing traditional risk factors and advancements in medical care have led to decreased cardiovascular mortality, the rise in metabolic risk factors and the potential for worsening outcomes in HF patients raise concerns. The shift from ischemic to metabolic drivers of HF also suggests that we may need to rethink our approach to prevention and treatment.
What are your thoughts on this evolving landscape of heart failure? Do you agree that we need to focus more on metabolic risk factors? Are current clinical trials adequately addressing the needs of diverse patient populations with HF? Share your opinions and insights in the comments below!
